<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRADAXA- dabigatran etexilate mesylate capsule </strong><br>Rebel Distributors Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. <br> PRADAXA® (dabigatran etexilate mesylate) capsules for oral use<br> Initial U.S. Approval: 2010</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">PRADAXA is a direct thrombin inhibitor indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with non-valvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> <a href="#i4i_indications_id_f90c2f0e-d179-4105-ac06-46ab20589cfb">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>For patients with CrCl &gt;30 mL/min: 150 mg orally, twice daily <a href="#i4i_section_id_3026b0ec-6375-46b9-8da7-f80242c94044">(2.1)</a>
</li>
<li>For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily <a href="#i4i_section_id_3026b0ec-6375-46b9-8da7-f80242c94044">(2.1)</a>
</li>
<li>Instruct patients not to chew, break, or open capsules <a href="#i4i_section_id_3026b0ec-6375-46b9-8da7-f80242c94044">(2.1)</a>
</li>
<li>Review recommendations for converting to or from other oral or parenteral anticoagulants <a href="#i4i_section_id_7ecf62d0-5edb-44ed-b3d5-a486af44855a">(2.2</a>, <a href="#i4i_section_id_88e2ea65-7615-45e6-9b6a-ed0edc22e0e6">2.3)</a>
</li>
<li>Temporarily discontinue PRADAXA before invasive or surgical procedures when possible, then restart promptly <a href="#i4i_section_id_c0bf347f-0ccf-437d-b425-48c94ebe6b8c">(2.4)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 75 mg and 150 mg <a href="#i4i_dosage_form_strength_id_8e054607-8d32-4b78-8418-f7ddfc971267">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#i4i_contraindications_id_13b6cb35-33e3-492a-93b9-c07b5b01bf05">(4)</a>
</li>
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to PRADAXA <a href="#i4i_contraindications_id_13b6cb35-33e3-492a-93b9-c07b5b01bf05">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: PRADAXA can cause serious and, sometimes, fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Promptly evaluate signs and symptoms of blood loss. <a href="#i4i_section_id_02b309bd-fd33-4323-860b-3d8e0d31606c">(5.1)</a>
</li>
<li>Temporary discontinuation: Avoid lapses in therapy to minimize risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <a href="#i4i_section_id_d38f58f9-22e8-4df1-9ba1-5448373ff322">(5.2)</a>
</li>
<li>P-gp inducers and inhibitors: Avoid coadministration of rifampin with PRADAXA because of effects on dabigatran exposure <a href="#i4i_section_id_c82952d2-35e7-40aa-b84a-87ae222fc03e">(5.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt;15%) are <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>-like symptoms and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#i4i_section_id_d35a3401-ea23-4548-b6e6-bf5f67692053">(6.1)</a> </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or <span class="Underline"><span class="Italics">www.fda.gov/medwatch</span></span></span></span>. </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Geriatric use: Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with age <a href="#i4i_geriatric_use_id_facf2c07-9a55-4c4f-9a15-c75e90a954df">(8.5)</a> </p></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Converting from or to Warfarin</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Converting from or to Parenteral Anticoagulants</a></h2>
<h2><a href="#section-2.4" class="toc">2.4  Surgery and Interventions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Temporary Discontinuation of PRADAXA</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6  Renal Impairment</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1  Instructions for Patients</a></h2>
<h2><a href="#section-15.2" class="toc">17.2  Bleeding</a></h2>
<h2><a href="#section-15.3" class="toc">17.3  Gastrointestinal Adverse Reactions</a></h2>
<h2><a href="#section-15.4" class="toc">17.4  Invasive or Surgical Procedures</a></h2>
<h2><a href="#section-15.5" class="toc">17.5  Concomitant Medications</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f90c2f0e-d179-4105-ac06-46ab20589cfb"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">PRADAXA is indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with non-valvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_0e77a50b-170d-49fc-849c-49375766f0d8"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3026b0ec-6375-46b9-8da7-f80242c94044"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Recommended Dose</h2>
<p class="First">For patients with creatinine clearance (CrCl) &gt;30 mL/min, the recommended dose of PRADAXA is 150 mg taken orally, twice daily, with or without food. For patients with CrCl 15-30 mL/min, the recommended dose is 75 mg twice daily <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#i4i_section_id_b323ae1c-9a93-4ac7-bd35-ad626adad1ea">(8.6)</a> and Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>. Dosing recommendations for patients with a CrCL &lt;15 mL/min or on dialysis cannot be provided.</p>
<p>Instruct patients to swallow the capsules whole. Breaking, chewing, or emptying the contents of the capsule can result in increased exposure <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>.</p>
<p>If a dose of PRADAXA is not taken at the scheduled time, the dose should be taken as soon as possible on the same day; the missed dose should be skipped if it cannot be taken at least 6 hours before the next scheduled dose. The dose of PRADAXA should not be doubled to make up for a missed dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ecf62d0-5edb-44ed-b3d5-a486af44855a"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Converting from or to Warfarin</h2>
<p class="First">When converting patients from warfarin therapy to PRADAXA, discontinue warfarin and start PRADAXA when the international normalized ratio (INR) is below 2.0.</p>
<p>When converting from PRADAXA to warfarin, adjust the starting time of warfarin based on creatinine clearance as follows:</p>
<ul>
<li>For CrCl &gt;50 mL/min, start warfarin 3 days before discontinuing PRADAXA.</li>
<li>For CrCl 31-50 mL/min, start warfarin 2 days before discontinuing PRADAXA.</li>
<li>For CrCl 15-30 mL/min, start warfarin 1 day before discontinuing PRADAXA.</li>
<li>For CrCl &lt;15 mL/min, no recommendations can be made.</li>
</ul>
<p>Because PRADAXA can contribute to an elevated INR, the INR will better reflect warfarin’s effect after PRADAXA has been stopped for at least 2 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88e2ea65-7615-45e6-9b6a-ed0edc22e0e6"></a><a name="section-2.3"></a><p></p>
<h2>2.3  Converting from or to Parenteral Anticoagulants</h2>
<p class="First">For patients currently receiving a parenteral anticoagulant, start PRADAXA 0 to 2 hours before the time that the next dose of the parenteral drug was to have been administered or at the time of discontinuation of a continuously administered parenteral drug (e.g., intravenous unfractionated heparin).</p>
<p>For patients currently taking PRADAXA, wait 12 hours (CrCl ≥30 mL/min) or 24 hours (CrCl &lt;30 mL/min) after the last dose of PRADAXA before initiating treatment with a parenteral anticoagulant <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0bf347f-0ccf-437d-b425-48c94ebe6b8c"></a><a name="section-2.4"></a><p></p>
<h2>2.4  Surgery and Interventions</h2>
<p class="First">If possible, discontinue PRADAXA 1 to 2 days (CrCl ≥50 mL/min) or 3 to 5 days (CrCl &lt;50 mL/min) before invasive or surgical procedures because of the increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Consider longer times for patients undergoing major surgery, spinal puncture, or placement of a spinal or epidural catheter or port, in whom complete hemostasis may be required <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#i4i_section_id_b323ae1c-9a93-4ac7-bd35-ad626adad1ea">(8.6)</a> and Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>.</p>
<p>If surgery cannot be delayed, there is an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#i4i_section_id_02b309bd-fd33-4323-860b-3d8e0d31606c">(5.1)</a>]</span></span>. This risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> should be weighed against the urgency of intervention <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#i4i_section_id_d38f58f9-22e8-4df1-9ba1-5448373ff322">(5.2)</a>]</span></span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> risk can be assessed by the ecarin clotting time (ECT). This test is a better marker of the anticoagulant activity of dabigatran than <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT), <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT)/INR, or <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span> (TT). If ECT is not available, the aPTT test provides an approximation of PRADAXA’s anticoagulant activity <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacodynamics_id_3f20d52d-4458-4c6e-94be-c749ed6175dd">(12.2)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_8e054607-8d32-4b78-8418-f7ddfc971267"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules with a light blue opaque cap imprinted in black with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted in black with "R150" (150 mg) or "R75" (75 mg).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_13b6cb35-33e3-492a-93b9-c07b5b01bf05"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">PRADAXA is contraindicated in patients with:</p>
<ul>
<li>Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#i4i_section_id_02b309bd-fd33-4323-860b-3d8e0d31606c">(5.1)</a> and Adverse Reactions <a href="#i4i_section_id_d35a3401-ea23-4548-b6e6-bf5f67692053">(6.1)</a>]</span></span>.</li>
<li>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to PRADAXA (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>) <span class="Italics"><span class="Emphasis">[see Adverse Reactions <a href="#i4i_section_id_d35a3401-ea23-4548-b6e6-bf5f67692053">(6.1)</a>]</span></span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_1a5bcdfa-1d54-4e24-bf6d-193915492c5a"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02b309bd-fd33-4323-860b-3d8e0d31606c"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">PRADAXA increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and can cause significant and, sometimes, fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> include the use of drugs that increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in general (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs) and labor and delivery. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>). Discontinue PRADAXA in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>In the RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) study, a life-threatening bleed (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that met one or more of the following criteria: fatal, symptomatic intracranial, reduction in hemoglobin of at least 5 grams per deciliter, transfusion of at least 4 units of blood, associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> requiring the use of intravenous inotropic agents, or necessitating <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>) occurred at an annualized rate of 1.5% and 1.8% for PRADAXA 150 mg and warfarin, respectively <span class="Italics"><span class="Emphasis">[see Adverse Reactions <a href="#i4i_section_id_d35a3401-ea23-4548-b6e6-bf5f67692053">(6.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d38f58f9-22e8-4df1-9ba1-5448373ff322"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Temporary Discontinuation of PRADAXA</h2>
<p class="First">Discontinuing anticoagulants, including PRADAXA, for active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, elective surgery, or invasive procedures places patients at an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Lapses in therapy should be avoided, and if anticoagulation with PRADAXA must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c82952d2-35e7-40aa-b84a-87ae222fc03e"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure</h2>
<p class="First">The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>.</p>
<p>P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin do not require dose adjustments. These results should not be extrapolated to other P-gp inhibitors <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_657b2579-8934-4dc7-a188-59a6f6ddf69c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d35a3401-ea23-4548-b6e6-bf5f67692053"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">The RE-LY study provided safety information on the use of two doses of PRADAXA and warfarin <span class="Italics"><span class="Emphasis">[see Clinical Studies <a href="#i4i_clinical_studies_id_14dc22cf-5421-4fa1-b643-4d8fc462fd8e">(14)</a>]</span></span>. The numbers of patients and their exposures are described in Table 1. Limited information is presented on the 110 mg dosing arm because this dose is not approved.</p>
<a name="id_76607668-d819-4d56-857f-566e4fd3b1e0"></a><table border="1">
<caption><span>Table 1 Summary of Treatment Exposure in RE-LY</span></caption>
<col width="30%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA 110 mg twice daily</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA 150 mg twice daily</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Warfarin</span></span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Total number treated</td>
<td class="Toprule" align="left" valign="top">5983</td>
<td class="Toprule" align="left" valign="top">6059</td>
<td align="left" valign="top">5998</td>
</tr>
<tr>
<td align="left" valign="top">Exposure</td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
</tr>
<tr>
<td align="left" valign="top">     &gt; 12 months</td>
<td align="left" valign="top">4936</td>
<td align="left" valign="top">4939</td>
<td align="left" valign="top">5193</td>
</tr>
<tr>
<td align="left" valign="top">     &gt; 24 months</td>
<td align="left" valign="top">2387</td>
<td align="left" valign="top">2405</td>
<td align="left" valign="top">2470</td>
</tr>
<tr>
<td align="left" valign="top">Mean exposure (months)</td>
<td align="left" valign="top">20.5</td>
<td align="left" valign="top">20.3 </td>
<td align="left" valign="top">21.3 </td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Total patient-years</td>
<td align="left" valign="top">10,242</td>
<td align="left" valign="top">10,261</td>
<td align="left" valign="top">10,659</td>
</tr>
</tbody>
</table>
<p>Because clinical studies are conducted under widely varying conditions and over varying lengths of time, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b6e4246-da81-43d9-834b-e60cfea2afec"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Drug Discontinuation in RE-LY</span></span></span></p>
<p>The rates of adverse reactions leading to treatment discontinuation were 21% for PRADAXA 150 mg and 16% for warfarin. The most frequent adverse reactions leading to discontinuation of PRADAXA were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and gastrointestinal events (i.e., <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed9ecd5f-200f-4ff8-be45-052c1703e0e1"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></span></span><span class="Italics"><span class="Emphasis"> [see Warnings and Precautions <a href="#i4i_section_id_02b309bd-fd33-4323-860b-3d8e0d31606c">(5.1)</a>]</span></span></p>
<p>Table 2 shows the number of patients experiencing serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during the treatment period in the RE-LY study, with the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate per 100 patient-years (%). Major bleeds fulfilled one or more of the following criteria: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with a reduction in hemoglobin of at least 2 grams per deciliter or leading to a transfusion of at least 2 units of blood, or symptomatic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with <span class="product-label-link" type="condition" conceptid="134734" conceptname="Compartment syndrome">compartment syndrome</span>, retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, intra-articular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or pericardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>). A life-threatening bleed met one or more of the following criteria: fatal, symptomatic intracranial bleed, reduction in hemoglobin of at least 5 grams per deciliter, transfusion of at least 4 units of blood, associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> requiring the use of intravenous inotropic agents, or necessitating <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>. <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhage</span> included intracerebral (<span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>), subarachnoid, and subdural bleeds.</p>
<a name="id_e126fb55-6aa4-44e0-90fb-458c42ba8727"></a><table border="0">
<caption><span>Table 2    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events* (per 100 Patient-Years)</span></caption>
<col width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="Botrule First Last">
<td class="Lrule" align="left" valign="top"> </td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA <br> 150 mg twice daily<br> N (%)</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Warfarin<br> N (%)</span></span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold"><span class="Emphasis">Hazard Ratio<br> (95% CI**)</span></span></td>
</tr></thead>
<tfoot><tr class="Last"><td class="Lrule Rrule" align="left" colspan="4" valign="top"> * Patients contributed multiple events and events were counted in multiple categories.<br> ** Confidence interval</td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule" align="left" valign="top">Randomized patients</td>
<td class="Toprule" align="left" valign="top">6076</td>
<td class="Toprule" align="left" valign="top">6022</td>
<td class="Rrule" align="left" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Patient-years</td>
<td align="left" valign="top">12,033</td>
<td align="left" valign="top">11,794</td>
<td class="Rrule" align="left" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhage</span></td>
<td align="left" valign="top">38 (0.3)</td>
<td align="left" valign="top">90 (0.8)</td>
<td class="Rrule" align="left" valign="top">0.41 (0.28, 0.60)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   Life-threatening bleed</td>
<td align="left" valign="top">179 (1.5)</td>
<td align="left" valign="top">218 (1.9)</td>
<td class="Rrule" align="left" valign="top">0.80 (0.66, 0.98)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   Major bleed</td>
<td align="left" valign="top">399 (3.3)</td>
<td align="left" valign="top">421 (3.6)</td>
<td class="Rrule" align="left" valign="top">0.93 (0.81, 1.07) </td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">   Any bleed</td>
<td align="left" valign="top">1993 (16.6)</td>
<td align="left" valign="top">2166 (18.4)</td>
<td class="Rrule" align="left" valign="top">0.91 (0.85, 0.96)</td>
</tr>
</tbody>
</table>
<p>The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics, with the exception of age, where there was a trend towards a higher incidence of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.4) for patients ≥75 years of age.</p>
<p>There was a higher rate of major <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeds</span> in patients receiving PRADAXA 150 mg than in patients receiving warfarin (1.6% vs. 1.1%, respectively, with a hazard ratio vs. warfarin of 1.5, 95% CI, 1.2 to 1.9), and a higher rate of any <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeds</span> (6.1% vs. 4.0%, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43cd5361-b1d6-438d-8fdb-ddb2a43e7cd6"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Gastrointestinal Adverse Reactions</span></span></span></p>
<p>Patients on PRADAXA 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs. 24% on warfarin). These were commonly <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>) and <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>-like symptoms (including <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, erosive <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="195309" conceptname="Eosinophilic gastritis">hemorrhagic gastritis</span>, hemorrhagic erosive <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, and <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5836890f-ff97-4241-a2ea-1b1355395c27"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span></span></p>
<p>In the RE-LY study, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>), allergic <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> were reported in &lt;0.1% of patients receiving PRADAXA.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a823398b-3f21-4441-8370-089f54843e00"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>. </p>
<p>P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin do not require dose adjustments. These results should not be extrapolated to other P-gp inhibitors <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062">(12.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_5e29f028-33cd-4a28-bcce-3bf360422d75"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_0c6fcd02-6141-4844-a984-f6c454104a45"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_duplicate_id_75023780-6398-4ea6-b7f8-1ad532e6c6fc"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First"><span class="Underline"><span class="Italics">   </span></span></p>
<p>There are no adequate and well-controlled studies in pregnant women.</p>
<p>Dabigatran has been shown to decrease the number of implantations when male and female rats were treated at a dosage of 70 mg/kg (about 2.6 to 3.0 times the human exposure at maximum recommended human dose [MRHD] of 300 mg/day based on area under the curve [AUC] comparisons) prior to mating and up to implantation (gestation Day 6). Treatment of pregnant rats after implantation with dabigatran at the same dose increased the number of dead offspring and caused excess vaginal/<span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> close to parturition. Although dabigatran increased the incidence of delayed or irregular ossification of fetal skull bones and vertebrae in the rat, it did not induce major malformations in rats or rabbits.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_d9dfe94b-0646-4a74-93a6-c7233535490a"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Safety and effectiveness of PRADAXA during labor and delivery have not been studied in clinical trials. Consider the risks of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in using PRADAXA in this setting <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#i4i_section_id_02b309bd-fd33-4323-860b-3d8e0d31606c">(5.1)</a>]</span></span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> of offspring and mother rats during labor in association with <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> occurred during treatment of pregnant rats from implantation (gestation Day 7) to weaning (lactation Day 21) with dabigatran at a dose of 70 mg/kg (about 2.6 times the human exposure at MRHD of 300 mg/day based on AUC comparisons).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e3440cd4-6545-4ac6-bdf5-3bd93ff14ede"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether dabigatran is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PRADAXA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_2399e89f-450e-4041-8087-e87a1fd572b9"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of PRADAXA in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_facf2c07-9a55-4c4f-9a15-c75e90a954df"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in the RE-LY study, 82% were 65 and over, while 40% were 75 and over. The risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with age, but the risk-benefit profile is favorable in all age groups <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#i4i_warnings_precautions_id_1a5bcdfa-1d54-4e24-bf6d-193915492c5a">(5)</a>, Adverse Reactions <a href="#i4i_section_id_d35a3401-ea23-4548-b6e6-bf5f67692053">(6.1)</a>, and Clinical Studies <a href="#i4i_clinical_studies_id_14dc22cf-5421-4fa1-b643-4d8fc462fd8e">(14)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b323ae1c-9a93-4ac7-bd35-ad626adad1ea"></a><a name="section-8.6"></a><p></p>
<h2>8.6  Renal Impairment</h2>
<p class="First">No dose adjustment of PRADAXA is recommended in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Reduce the dose of PRADAXA in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 15-30 mL/min) <span class="Italics"><span class="Emphasis">[see Dosage and Administration <a href="#i4i_section_id_3026b0ec-6375-46b9-8da7-f80242c94044">(2.1)</a>]</span></span>. Dosing recommendations for patients with CrCl &lt;15 mL/min or on dialysis cannot be provided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_13583e3c-bb52-4956-9692-2e4c56c99675"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may lead to hemorrhagic complications. There is no antidote to dabigatran etexilate or dabigatran. In the event of hemorrhagic complications, initiate appropriate clinical support, discontinue treatment with PRADAXA, and investigate the source of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Dabigatran is primarily excreted in the urine; therefore, maintain adequate <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. Dabigatran can be dialyzed (protein binding is low), with the removal of about 60% of drug over 2 to 3 hours; however, data supporting this approach are limited. Consider surgical hemostasis or the transfusion of fresh frozen plasma or red blood cells. There is some experimental evidence to support the role of activated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> complex concentrates (e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X; however, their usefulness in clinical settings has not been established. Consider administration of platelet concentrates in cases where <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> is present or long-acting antiplatelet drugs have been used. Measurement of aPTT or ECT may help guide therapy <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology (12.2)]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_4b2e7ad1-bb2b-4848-8ddb-2f4b2bdfa48b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is β-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate. The empirical formula is C<span class="Sub">34</span>H<span class="Sub">41</span>N<span class="Sub">7</span>O<span class="Sub">5</span> • CH<span class="Sub">4</span>O<span class="Sub">3</span>S and the molecular weight is 723.86 (mesylate salt), 627.75 (free base). The structural formula is:</p>
<div class="Figure"><img alt="Praxada (dabigatran etexilate mesylate) structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e&amp;name=5db7f199-8752-4d24-85f7-e34ca8f4d02e-01.jpg"></div>
<p>Dabigatran etexilate mesylate is a yellow-white to yellow powder. A saturated solution in pure water has a solubility of 1.8 mg/mL. It is freely soluble in methanol, slightly soluble in ethanol, and sparingly soluble in isopropanol.</p>
<p>The 150 mg capsule for oral administration contains 172.95 mg dabigatran etexilate mesylate, which is equivalent to 150 mg of dabigatran etexilate, and the following inactive ingredients: acacia, dimethicone, hypromellose, hydroxypropyl cellulose, talc, and tartaric acid. The capsule shell is composed of carrageenan, FD&amp;C Blue No. 2, FD&amp;C Yellow No. 6, hypromellose, potassium chloride, titanium dioxide, and black edible ink. The 75 mg capsule contains 86.48 mg dabigatran etexilate mesylate, equivalent to 75 mg dabigatran etexilate, and is otherwise similar to the 150 mg capsule.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_989b5417-f616-4607-b664-ac4c94203ed6"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_9e638f6d-d7fc-4e44-ae7e-25edad6682e3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_3f20d52d-4458-4c6e-94be-c749ed6175dd"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">At recommended therapeutic doses, dabigatran etexilate prolongs the aPTT, ECT, and TT. With an oral dose of 150 mg twice daily the median peak aPTT is approximately 2x control. Twelve hours after the last dose the median aPTT is 1.5x control, with less than 10% of patients exceeding 2x control. In the RE-LY trial, the median (10<span class="Sup">th</span> to 90<span class="Sup">th</span> percentile) trough aPTT in patients receiving the 150 mg dose was 52 (40 to 76) seconds. The median (10<span class="Sup">th</span> to 90<span class="Sup">th</span> percentile) trough ECT in patients receiving the 150 mg dose was 63 (44 to 103) seconds. The INR test is relatively insensitive to the activity of dabigatran and may or may not be elevated in patients on PRADAXA. When converting a patient from PRADAXA to warfarin therapy, the INR is unlikely to be useful until at least 2 days after discontinuation of PRADAXA.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c09556f7-3a53-48d4-b783-906e322a8c53"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Cardiac Electrophysiology</span></span></span></p>
<p>No prolongation of the QTc interval was observed with dabigatran etexilate at doses up to 600 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_57923ecc-274d-435e-a073-221a1fed9062"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Dabigatran etexilate mesylate is absorbed as the dabigatran etexilate ester. The ester is then hydrolyzed, forming dabigatran, the active moiety. Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and dabigatran have similar pharmacological activity. Pharmacokinetics described here refer to the sum of dabigatran and its glucuronides. Dabigatran displays dose-proportional pharmacokinetics in healthy subjects and patients in the range of doses from 10 to 400 mg.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af9de9bd-6cb2-49b7-aa23-f71be6cbf6c6"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Absorption</span></span></span></p>
<p>The absolute bioavailability of dabigatran following oral administration of dabigatran etexilate is approximately 3 to 7%. Dabigatran etexilate is a substrate of the efflux transporter P-gp. After oral administration of dabigatran etexilate in healthy volunteers, C<span class="Sub">max</span> occurs at 1 hour post-administration in the fasted state. Coadministration of PRADAXA with a high-fat meal delays the time to C<span class="Sub">max</span> by approximately 2 hours but has no effect on the bioavailability of dabigatran; PRADAXA may be administered with or without food. </p>
<p>The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation. PRADAXA capsules should therefore not be broken, chewed, or opened before administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0664960e-e8b0-4699-b673-1dc8bf35aee9"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Distribution</span></span></span></p>
<p>Dabigatran is approximately 35% bound to human plasma proteins. The red blood cell to plasma partitioning of dabigatran measured as total radioactivity is less than 0.3. The volume of distribution of dabigatran is 50 to 70 L. Dabigatran pharmacokinetics are dose proportional after single doses of 10 to 400 mg. Given twice daily, dabigatran’s accumulation factor is approximately two.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a87d665b-9c4f-4be9-bc79-6cd6f64a91f7"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Elimination</span></span></span></p>
<p>Dabigatran is eliminated primarily in the urine. Renal clearance of dabigatran is 80% of total clearance after intravenous administration. After oral administration of radiolabeled dabigatran, 7% of radioactivity is recovered in urine and 86% in feces. The half-life of dabigatran in healthy subjects is 12 to 17 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37537582-b2ab-4cb6-be02-b8c4fd2b90f7"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Metabolism</span></span></span></p>
<p>After oral administration, dabigatran etexilate is converted to dabigatran. The cleavage of the dabigatran etexilate by esterase-catalyzed hydrolysis to the active principal dabigatran is the predominant metabolic reaction. Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes. Dabigatran is subject to conjugation forming pharmacologically active acyl glucuronides. Four positional isomers, 1-O, 2-O, 3-O, and 4-O-acylglucuronide exist, and each accounts for less than 10% of total dabigatran in plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_924e0cd1-c1ec-4ac1-bae2-2977f2e29cfa"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></span></p>
<p>An open, parallel-group single-center study compared dabigatran pharmacokinetics in healthy subjects and patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> receiving a single dose of PRADAXA 150 mg. Based on pharmacokinetic modeling, estimated exposure to dabigatran increases with the severity of renal function impairment (Table 3). Similar findings were observed in the RE-LY trial.</p>
<a name="id_c384102a-7efc-4445-9522-85fcf9384392"></a><table border="1">
<caption><span>Table 3 Estimated Pharmacokinetic Parameters of Dabigatran by Renal Function</span></caption>
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Renal Function</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">CrCl (mL/min)</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Increase in AUC</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Increase in C<span class="Sub">max</span></span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">t<span class="Sub">1/2</span><br> (h)</span></span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Normal</span></span></td>
<td class="Toprule" align="left" valign="top">80</td>
<td class="Toprule" align="left" valign="top">1x</td>
<td class="Toprule" align="left" valign="top">1x</td>
<td align="left" valign="top">13</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Mild</span></span></td>
<td align="left" valign="top">50</td>
<td align="left" valign="top">1.5x</td>
<td align="left" valign="top">1.1x</td>
<td align="left" valign="top">15</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Moderate</span></span></td>
<td align="left" valign="top">30</td>
<td align="left" valign="top">3.2x</td>
<td align="left" valign="top">1.7x</td>
<td align="left" valign="top">18</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52c7b10d-f84c-46de-9d66-9b61dbd1d3f7"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></span></p>
<p>Administration of PRADAXA in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B) showed a large inter-subject variability, but no evidence of a consistent change in exposure or pharmacodynamics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80f88ab5-4941-4e15-bd52-8a25d7acdd3b"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="Emphasis">Drug Interactions</span></span></span></p>
<p><span class="Italics"><span class="Emphasis">Impact of Other Drugs on Dabigatran</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e30864a-de27-4dd5-9659-9b068e3bfb7c"></a><a name="section-11.3.8"></a><p></p>
<h3>P-gp Inducers </h3>
<p class="First"><span class="Italics"><span class="Emphasis">Rifampin:</span></span> Rifampin 600 mg once daily for 7 days followed by a single dose of dabigatran decreased its AUC and C<span class="Sub">max</span> by 66% and 67%, respectively. By Day 7 after cessation of rifampin treatment, dabigatran exposure was close to normal <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#i4i_section_id_c82952d2-35e7-40aa-b84a-87ae222fc03e">(5.3)</a> and Drug Interactions <a href="#i4i_interactions_id_a823398b-3f21-4441-8370-089f54843e00">(7)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0f0e224-7394-4fc7-8ce7-cf6e308e259f"></a><a name="section-11.3.9"></a><p></p>
<h3>P-gp Inhibitors</h3>
<p class="First">In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. Any observed changes in C<span class="Sub">max</span> and AUC are described below.</p>
<p><span class="Italics"><span class="Emphasis">Dronedarone</span></span>: Exposure to dabigatran is higher when it is administered with dronedarone than when it is administered alone (1.7- to 2-fold).</p>
<p><span class="Italics"><span class="Emphasis">Ketoconazole</span></span>: Ketoconazole increased dabigatran AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg.</p>
<p><span class="Italics"><span class="Emphasis">Verapamil</span></span>: When dabigatran etexilate was coadministered with oral verapamil, the C<span class="Sub">max</span> and AUC of dabigatran were increased. The extent of increase depends on the formulation of verapamil and timing of administration. If verapamil is present in the gut when dabigatran is taken, it will increase exposure to dabigatran with the greatest increase observed when a single dose of immediate-release verapamil is given one hour prior to dabigatran (AUC increased by a factor of 2.4). If verapamil is given 2 hours after dabigatran, the increase in AUC is negligible. In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received verapamil.</p>
<p><span class="Italics"><span class="Emphasis">Amiodarone</span></span>: When dabigatran etexilate was coadministered with a single 600 mg oral dose of amiodarone, the dabigatran AUC and C<span class="Sub">max</span> increased by 58% and 50%, respectively. The increase in exposure was mitigated by a 65% increase in the renal clearance of dabigatran in the presence of amiodarone. The increase in renal clearance may persist after amiodarone is discontinued because of amiodarone’s long half-life. In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received amiodarone.</p>
<p><span class="Italics"><span class="Emphasis">Quinidine</span></span>: Quinidine was given as 200 mg dose every 2 hours up to a total dose of 1000 mg. Dabigatran etexilate was given over 3 consecutive days, the last evening dose on Day 3 with or without quinidine pre-dosing. Concomitant quinidine administration increased dabigatran’s AUC and C<span class="Sub">max</span> by 53% and 56%, respectively.</p>
<p><span class="Italics"><span class="Emphasis">Clarithromycin:</span></span> Coadministered clarithromycin had no impact on the exposure to dabigatran.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_918ba5d9-3c43-4316-9b71-72cddfd42edb"></a><a name="section-11.3.10"></a><p></p>
<h3>Other Drugs</h3>
<p class="First"><span class="Italics"><span class="Emphasis">Clopidogrel:</span></span> When dabigatran etexilate was given concomitantly with a loading dose of 300 mg or 600 mg clopidogrel, the dabigatran AUC and C<span class="Sub">max</span> increased by approximately 30% and 40%, respectively. The concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> compared to clopidogrel monotherapy. When comparing combined treatment and the respective mono-treatments, the coagulation measures for dabigatran’s effect (aPTT, ECT, and TT) remained unchanged, and inhibition of platelet aggregation (IPA), a measurement of clopidogrel’s effect, remained unchanged.</p>
<p><span class="Italics"><span class="Emphasis">Enoxaparin:</span></span> Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.</p>
<p><span class="Italics"><span class="Emphasis">Diclofenac, Ranitidine, and Digoxin:</span></span> None of these drugs alters exposure to dabigatran.</p>
<p>In RE-LY, dabigatran plasma samples were also collected. The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f824621-1f62-4322-a919-c0547575a78c"></a><a name="section-11.3.10.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Emphasis">Impact of Dabigatran on Other Drugs</span></span></p>
<p>In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_e5233ab1-ea1e-4d26-95a2-56c0f1a144b9"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_9452d9b6-4941-47b9-885b-9ee8e4bfb7d2"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Dabigatran was not carcinogenic when administered by oral gavage to mice and rats for up to 2 years. The highest doses tested (200 mg/kg/day) in mice and rats were approximately 3.6 and 6 times, respectively, the human exposure at MRHD of 300 mg/day based on AUC comparisons.</p>
<p>Dabigatran was not mutagenic in <span class="Italics"><span class="Emphasis">in vitro</span></span> tests, including bacterial reversion tests, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the <span class="Italics"><span class="Emphasis">in vivo</span></span> micronucleus assay in rats.</p>
<p>In the rat fertility study with oral gavage doses of 15, 70, and 200 mg/kg, males were treated for 29 days prior to mating, during mating up to scheduled termination, and females were treated 15 days prior to mating through gestation Day 6. No adverse effects on male or female fertility were observed at 200 mg/kg or 9 to 12 times the human exposure at MRHD of 300 mg/day based on AUC comparisons. However, the number of implantations decreased in females receiving 70 mg/kg, or 3 times the human exposure at MRHD based on AUC comparisons.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_14dc22cf-5421-4fa1-b643-4d8fc462fd8e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The clinical evidence for the efficacy of PRADAXA was derived from RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy), a multi-center, multi-national, randomized parallel group trial comparing two blinded doses of PRADAXA (110 mg twice daily and 150 mg twice daily) with open-label warfarin (dosed to target INR of 2 to 3) in patients with non-valvular, persistent, paroxysmal, or permanent <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and one or more of the following additional risk factors:</p>
<ul>
<li>Previous <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack (TIA), or systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></li>
<li>Left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40% </li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, ≥ New York Heart Association Class 2</li>
<li>Age ≥75 years</li>
<li>Age ≥65 years and one of the following: <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD), or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> </li>
</ul>
<p>The primary objective of this study was to determine if PRADAXA was non-inferior to warfarin in reducing the occurrence of the composite endpoint, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (ischemic and hemorrhagic) and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. The study was designed to ensure that PRADAXA preserved more than 50% of warfarin’s effect as established by previous randomized, placebo-controlled trials of warfarin in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. Statistical superiority was also analyzed.</p>
<p>A total of 18,113 patients were randomized and followed for a median of 2 years. The patient’s mean age was 71.5 years and the mean CHADS<span class="Sub">2</span> score was 2.1. The patient population was 64% male, 70% Caucasian, 16% Asian, and 1% black. Twenty percent of patients had a history of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA and 50% were Vitamin K antagonist (VKA) naïve, defined as less than 2 months total lifetime exposure to a VKA. Thirty-two percent of the population had never been exposed to a VKA. Concomitant diseases of patients in this trial included <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> 79%, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 23%, and CAD 28%. At baseline, 40% of patients were on aspirin and 6% were on clopidogrel. For patients randomized to warfarin, the mean percentage of time in therapeutic range (INR 2 to 3) was 64%; the mean percentages of time INR measurements were greater than 4 or less than 1.5 were 2% and 5%, respectively.</p>
<p>Relative to warfarin and to PRADAXA 110 mg twice daily, PRADAXA 150 mg twice daily significantly reduced the primary composite endpoint of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> (see Table 4 and Figure 1). </p>
<a name="id_006c6704-5191-4300-af37-ebe43a472a97"></a><table border="1">
<caption><span>Table 4 First Occurrence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in the RE-LY Study</span></caption>
<col width="40%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"> </td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA <br> 150 mg twice daily</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA <br> 110 mg twice daily</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Warfarin</span></span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Patients randomized</td>
<td class="Toprule" align="left" valign="top">6076</td>
<td class="Toprule" align="left" valign="top">6015</td>
<td align="left" valign="top">6022</td>
</tr>
<tr>
<td align="left" valign="top">Patients (%) with events </td>
<td align="left" valign="top">134 (2.2%)</td>
<td align="left" valign="top">183 (3%)</td>
<td align="left" valign="top">202 (3.4%)</td>
</tr>
<tr>
<td align="left" valign="top">Hazard ratio vs. warfarin (95% CI)</td>
<td align="left" valign="top">0.65 (0.52, 0.81)</td>
<td align="left" valign="top">0.90 (0.74, 1.10)</td>
<td align="left" valign="top"> </td>
</tr>
<tr>
<td align="left" valign="top">   P-value for superiority</td>
<td align="left" valign="top">0.0001</td>
<td align="left" valign="top">0.3</td>
<td align="left" valign="top"> </td>
</tr>
<tr>
<td align="left" valign="top">Hazard ratio vs. PRADAXA 110 mg (95% CI)</td>
<td align="left" valign="top">0.72 (0.58, 0.90)</td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">   P-value for superiority</td>
<td align="left" valign="top">0.004</td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
</tr>
</tbody>
</table>
<p> Figure 1 Kaplan-Meier Curve Estimate of Time to First <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> </p>
<p><img alt="Kaplan-Meier Curve Estimate of Time to First <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span>" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e&amp;name=5db7f199-8752-4d24-85f7-e34ca8f4d02e-02.jpg"></p>
<p>The contributions of the components of the composite endpoint, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by subtype, are shown in Table 5. The treatment effect was primarily a reduction in <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. PRADAXA 150 mg twice daily significantly reduced both ischemic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span> relative to warfarin.</p>
<a name="id_d733393c-3e71-4ab0-aa96-bfe1bb4a7cfd"></a><table border="1">
<caption><span>Table 5 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in the RE-LY Study</span></caption>
<col width="25%">
<col align="center" width="25%">
<col align="center" width="30%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"> </td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA<br> 150 mg twice daily</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Warfarin </span></span></td>
<td align="left" valign="top">
<span class="Bold"><span class="Emphasis">Hazard ratio vs. warfarin</span></span><br><span class="Bold"><span class="Emphasis">(95% CI) </span></span>
</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Patients randomized</td>
<td class="Toprule" align="left" valign="top">6076</td>
<td class="Toprule" align="left" valign="top">6022</td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis"> </span></span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </td>
<td align="left" valign="top">122 </td>
<td align="left" valign="top">186 </td>
<td align="left" valign="top">0.64 (0.51, 0.81)</td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></td>
<td align="left" valign="top">103</td>
<td align="left" valign="top">134</td>
<td align="left" valign="top">0.75 (0.58, 0.97)</td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic stroke</span></td>
<td align="left" valign="top">12</td>
<td align="left" valign="top">45</td>
<td align="left" valign="top">0.26 (0.14, 0.49)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></td>
<td align="left" valign="top">13</td>
<td align="left" valign="top">21</td>
<td align="left" valign="top">0.61 (0.30, 1.21)</td>
</tr>
</tbody>
</table>
<p>The efficacy of PRADAXA 150 mg twice daily was generally consistent across major subgroups (see Figure 2).</p>
<p> Figure 2 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> Hazard Ratios by Baseline Characteristics </p>
<p><img alt="<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> Hazard Ratios by Baseline Characteristics" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e&amp;name=5db7f199-8752-4d24-85f7-e34ca8f4d02e-03.jpg"></p>
<p>Centers were ranked post hoc by the percentage of time that warfarin-treated patients were in therapeutic range (INR 2 to 3). Findings for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, all-cause mortality, and major bleeds are shown for centers above and below the median level of INR control in Table 6. The benefits of PRADAXA 150 mg relative to warfarin were most apparent in patients enrolled at centers with INR control below the median.</p>
<a name="id_d692b950-29f1-403d-a843-d169edc4768d"></a><table border="1">
<caption><span>Table 6 Center INR Control in the RE-LY Study </span></caption>
<col width="33%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"> </td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Centers with INR control <br> below the median of 67%</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Centers with INR control<br> above the median of 67%</span></span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>/systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></td>
<td class="Toprule" align="left" valign="top">0.57 (0.42, 0.76)</td>
<td align="left" valign="top">0.76 (0.55, 1.05)</td>
</tr>
<tr>
<td align="left" valign="top">All-cause mortality</td>
<td align="left" valign="top">0.78 (0.66, 0.93)</td>
<td align="left" valign="top">1.01 (0.84, 1.23)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Major bleed</td>
<td align="left" valign="top">0.82 (0.68, 0.99)</td>
<td align="left" valign="top">1.08 (0.89, 1.31)</td>
</tr>
</tbody>
</table>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was numerically greater in patients who received PRADAXA (1.5% for 150 mg dose) than in those who received warfarin (1.1%).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_fbe3a47c-1146-4d3b-aae0-2b4288a1df63"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">PRADAXA 75 mg capsules have a light blue opaque cap imprinted with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted with "R75". The color of the imprinting is black. The capsules are supplied in the packages listed:</p>
<ul>
<li>NDC 0597-0107-54    Unit of use bottle of 60 capsules</li>
<li>NDC 0597-0107-60    <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> package containing 60 capsules (10 x 6 capsule <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards) </li>
</ul>
<p>PRADAXA 150 mg capsules have a light blue opaque cap imprinted with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted with "R150". The color of the imprinting is black. The capsules are supplied in the packages listed:</p>
<ul>
<li>NDC 0597-0135-54    Unit of use bottle of 60 capsules</li>
<li>NDC 0597-0135-60    <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> package containing 60 capsules (10 x 6 capsule <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards) </li>
</ul>
<p><span class="Underline"><span class="Italics"><span class="Emphasis">Bottles</span></span></span></p>
<p>Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). Once opened, the product must be used within 30 days. Keep the bottle tightly closed. Store in the original package to protect from moisture.</p>
<p><span class="Underline"><span class="Italics">  <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span></span></span></p>
<p>Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). Store in the original package to protect from moisture.</p>
<p>Keep out of the reach of children.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97e39392-bc64-4e05-a6fe-a6f80eb22edf"></a><a name="section-14.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_af851301-3899-48d2-9dac-a93934160046"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics"><span class="Emphasis">See Medication Guide</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_703ecf58-4e04-4543-b7d9-f4bac0865236"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Instructions for Patients</h2>
<ul>
<li>Tell patients to take PRADAXA exactly as prescribed.</li>
<li>Remind patients not to discontinue PRADAXA without talking to the health care provider who prescribed it.</li>
<li>Advise patients not to chew or break the capsules before swallowing them and not to open the capsules and take the pellets alone (e.g., sprinkled over food or into beverages).</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74f414af-8c49-4cee-8252-b6401a95c687"></a><a name="section-15.2"></a><p></p>
<h2>17.2  Bleeding</h2>
<p class="First">Inform patients that they may bleed more easily, may bleed longer, and should call their health care provider for any signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Instruct patients to seek emergency care right away if they have any of the following, which may be a sign or symptom of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </p>
<ul>
<li>Unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> (<span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> that appear without known cause or that get bigger)</li>
<li>Pink or brown urine</li>
<li>Red or black, <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span> up blood</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> blood, or vomit that looks like coffee grounds</li>
</ul>
<p>Instruct patients to call their health care provider or to get prompt medical attention if they experience any signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in a joint</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>Reoccurring <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleeds</span></li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from gums</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> from a cut that takes a long time to stop</li>
<li>Menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> that is heavier than normal</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5499f94e-5169-4e67-beeb-28e7671b62e5"></a><a name="section-15.3"></a><p></p>
<h2>17.3  Gastrointestinal Adverse Reactions</h2>
<p class="First">Instruct patients to call their health care provider if they experience any signs or symptoms of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> or <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> (<span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>), burning, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">Epigastric discomfort</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (gastric <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>)</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_08476e04-2226-4993-afb5-4971681dee23"></a><a name="section-15.4"></a><p></p>
<h2>17.4  Invasive or Surgical Procedures</h2>
<p class="First">Instruct patients to inform their health care provider that they are taking PRADAXA before any invasive procedure (including dental procedures) is scheduled.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fe3481b-196e-4a13-baac-21fd8d03c5db"></a><a name="section-15.5"></a><p></p>
<h2>17.5  Concomitant Medications</h2>
<p class="First">Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take so their health care provider knows about other treatments that may affect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk (e.g., aspirin or NSAIDs) or dabigatran exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9f1d9d2-d369-42da-90e5-e0e6c45cbab2"></a><a name="section-15.6"></a><p></p>
<p class="First">Distributed by:<br> Boehringer Ingelheim Pharmaceuticals, Inc.<br> Ridgefield, CT 06877 USA</p>
<p>Copyright 2011 Boehringer Ingelheim Pharmaceuticals, Inc.<br> ALL RIGHTS RESERVED</p>
<p>75461-02<br> IT5060BC072011</p>
<p>75457-02<br> IT5400B</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_f8258c02-d741-4198-b8d2-2324bf191623"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold"><span class="Emphasis">MEDICATION GUIDE<br> PRADAXA (pra dax´ a)<br> (dabigatran etexilate mesylate) <br> capsules</span></span></p>
<p>Read this Medication Guide before you start taking PRADAXA and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold"><span class="Emphasis">What is the most important information I should know about PRADAXA?</span></span></p>
<ul>
<li>PRADAXA can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which can be serious, and sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This is because PRADAXA is a blood thinner medicine that lowers the chance of blood clots forming in your body.</li>
<li>
<span class="Bold"><span class="Emphasis">You may have a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if you take PRADAXA and:</span></span><ul>
<li>are over 75 years old</li>
<li>have kidney problems</li>
<li>have stomach or intestine <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is recent or keeps coming back, or you have a <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span></li>
<li>take other medicines that increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including: Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.<ul>
<li>aspirin or aspirin containing products</li>
<li>long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li>
<li>warfarin sodium (Coumadin®, Jantoven®)</li>
<li>a medicine that contains heparin</li>
<li>clopidogrel (Plavix®) </li>
<li>prasugrel (Effient®)</li>
</ul>
</li>
</ul>
</li>
<li>PRADAXA can increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> because it lessens the ability of your blood to clot. While you take PRADAXA: <br><span class="Bold"><span class="Emphasis">Call your doctor or get medical help right away if you have any of these signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></span><br><span class="Bold"><span class="Emphasis">Take PRADAXA exactly as prescribed. Do not stop taking PRADAXA without first talking to the doctor who prescribes it for you. Stopping PRADAXA may increase your risk of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span></span><br><br> PRADAXA may need to be stopped, if possible, for one or more days before any surgery, or medical or dental procedure. If you need to stop taking PRADAXA for <span class="Bold"><span class="Emphasis">any reason</span></span>, talk to the doctor who prescribed PRADAXA for you to find out when you should stop taking it. Your doctor will tell you when to start taking PRADAXA again after your surgery or procedure.<br><br><span class="Bold"><span class="Emphasis">See "What are the possible side effects of PRADAXA?" for more information about side effects.</span></span><ul>
<li>you may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> more easily</li>
<li>it may take longer for any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop</li>
</ul>
</li>
</ul>
<p><span class="Bold"><span class="Emphasis">What is PRADAXA?</span></span></p>
<p>PRADAXA is a prescription medicine used to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and blood clots in people who have a medical condition called <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. With <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, part of the heart does not beat the way it should. This can lead to blood clots forming and increase your risk of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. PRADAXA is a blood thinner medicine that lowers the chance of blood clots forming in your body.</p>
<p>It is not known if PRADAXA is safe and works in children.</p>
<p><span class="Bold"><span class="Emphasis">Who should not take PRADAXA?</span></span></p>
<p><span class="Bold"><span class="Emphasis">Do not take PRADAXA if you:</span></span></p>
<ul>
<li>currently have certain types of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Talk to your doctor, before taking PRADAXA if you currently have unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>have had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to PRADAXA. Ask your doctor if you are not sure.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">What should I tell my doctor before taking PRADAXA? </span></span></p>
<p>Before you take PRADAXA, tell your doctor if you:</p>
<ul>
<li>have kidney problems</li>
<li>have ever had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have ever had <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span></li>
<li>have any other medical condition</li>
<li>are pregnant or plan to become pregnant. It is not known if PRADAXA will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if PRADAXA passes into your breast milk. <br><br>Tell all of your doctors and dentists that you are taking PRADAXA. They should talk to the doctor who prescribed PRADAXA for you, before you have <span class="Bold"><span class="Emphasis">any</span></span> surgery, or medical or dental procedure. <br><br><span class="Bold"><span class="Emphasis">Tell your doctor about all the medicines you take, including</span></span> prescription and non-prescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way PRADAXA works. Certain medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. See "<span class="Bold"><span class="Emphasis">What is the most important information I should know about PRADAXA</span></span>?" <br><br>Especially tell your doctor if you take: <br>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.<ul><li>rifampin (Rifater, Rifamate, Rimactane, Rifadin)</li></ul>
</li>
</ul>
<p><span class="Bold"><span class="Emphasis">How should I take PRADAXA?</span></span></p>
<ul>
<li><span class="Bold"><span class="Emphasis">Take PRADAXA exactly as prescribed by your doctor.</span></span></li>
<li>Do not take PRADAXA more often than your doctor tells you to.</li>
<li>You can take PRADAXA with or without food.</li>
<li>Swallow PRADAXA capsules whole. Do not break, chew, or empty the pellets from the capsule.</li>
<li>If you miss a dose of PRADAXA, take it as soon as you remember. If your next dose is less than 6 hours away, skip the missed dose. Do not take two doses of PRADAXA at the same time.</li>
<li>Your doctor will decide how long you should take PRADAXA. <span class="Bold"><span class="Emphasis">Do not stop taking PRADAXA without first talking with your doctor. Stopping PRADAXA may increase your risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span></span>
</li>
<li>Do not run out of PRADAXA. Refill your prescription before you run out. If you plan to have surgery, or a medical or a dental procedure, tell your doctor and dentist that you are taking PRADAXA. You may have to stop taking PRADAXA for a short time. See "What is the most important information I should know about PRADAXA?"</li>
<li>If you take too much PRADAXA, go to the nearest hospital emergency room or call your doctor or the Poison Control Center right away.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">What are the possible side effects of PRADAXA?</span></span></p>
<p>PRADAXA can cause serious side effects.</p>
<ul>
<li>See "What is the most important information I should know about PRADAXA?"</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>. In some people, PRADAXA can cause symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. Tell your doctor or get medical help right away if you get any of the following symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with PRADAXA: <ul>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face or tongue</li>
<li>trouble breathing or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></li>
<li>feeling dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span></li>
</ul>
</li>
</ul>
<p>Common side effects of PRADAXA include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, or burning </li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of PRADAXA. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold"><span class="Emphasis">How should I store PRADAXA?</span></span></p>
<ul>
<li>Store PRADAXA at room temperature between 59°F to 86°F (15°C to 30°C). After opening the bottle, use PRADAXA within 30 days. Safely throw away any unused PRADAXA after 30 days.</li>
<li>Store PRADAXA in the original package to keep it dry. Keep the bottle tightly closed.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Keep PRADAXA and all medicines out of the reach of children.</span></span></p>
<p><span class="Bold"><span class="Emphasis">General information about PRADAXA</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PRADAXA for a condition for which it was not prescribed. Do not give your PRADAXA to other people, even if they have the same symptoms. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about PRADAXA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about PRADAXA that is written for health professionals.</p>
<p>For more information, go to www.PRADAXA.com or call 1-800-542-6257 or (TTY) 1-800-459-9906.</p>
<p><span class="Bold"><span class="Emphasis">What are the ingredients in PRADAXA?</span></span></p>
<p>Active ingredient: dabigatran etexilate mesylate</p>
<p>Inactive ingredients: acacia, dimethicone, hypromellose, hydroxypropyl cellulose, talc, and tartaric acid. The capsule shell is composed of carrageenan, FD&amp;C Blue No. 2, FD&amp;C Yellow No. 6, hypromellose, potassium chloride, titanium dioxide, and black edible ink.</p>
<p>Distributed by:<br> Boehringer Ingelheim Pharmaceuticals, Inc.<br> Ridgefield, CT 06877 USA</p>
<p>Revised: March 2011<br> This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Copyright 2011 Boehringer Ingelheim Pharmaceuticals, Inc.<br> ALL RIGHTS RESERVED</p>
<p>75461-02<br> IT5060BC072011</p>
<p>75457-02<br> IT5400B</p>
<p>Repackaged by </p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<p>Coumadin® is a registered trademark for Bristol-Myers Squibb<br> Jantoven® is a registered trademark for USL Pharma<br> Plavix® is a registered trademark of sanofi aventis <br> Effient® is a registered trademark of Eli Lilly and Company </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b3b2821b-db10-45dc-9d63-6a3307ed2fad"></a><a name="section-17"></a><p></p>
<h1>Principal Display panel</h1>
<p class="First"><img alt="Pradaxa 150mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e&amp;name=5db7f199-8752-4d24-85f7-e34ca8f4d02e-04.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRADAXA 		
					</strong><br><span class="contentTableReg">dabigatran etexilate mesylate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-899(NDC:0597-0135)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dabigatran etexilate mesylate</strong> (dabigatran etexilate) </td>
<td class="formItem">dabigatran etexilate</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARRAGEENAN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light Blue) , WHITE (Cream colored) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">R150;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-899-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022512</td>
<td class="formItem">10/26/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5db7f199-8752-4d24-85f7-e34ca8f4d02e</div>
<div>Set id: 5db7f199-8752-4d24-85f7-e34ca8f4d02e</div>
<div>Version: 1</div>
<div>Effective Time: 20101123</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
